BIOMAT Database Logo BIOMAT Database Logo

Thiadiazole derivatives: highly potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replications in vitro. 1997

M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
Rational Drug Design Laboratories, Matsukawa-machi, Fukushima, Japan.

We have recently reported that thiadiazole (TDA) derivatives are highly potent inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. These compounds belong to the family of nonnucleoside reverse transcriptase inhibitors (NNRTIs). In an attempt to develop more effective and pharmacologically favorable compounds, novel TDA derivatives have been synthesized and examined for their anti-HIV-1 activity in vitro. Among them, RD4-2217 was found to be the most potent inhibitor of HIV-1 replication. It inhibited replication of the HTLV-IIIB strain in MT-4 cells at a concentration of 6 nM. RD4-2217 was also inhibitory to clinical isolates and zidovudine-resistant mutants of HIV-1. The combination of RD4-2217 with zidovudine or the protease inhibitor A-75925 synergistically inhibited HIV-1 replication. Studies on the emergence of drug-resistant mutants revealed that, although much higher concentrations (1-10 microM) were required, RD4-2217 completely suppressed the breakthrough of HIV-1 in the supernatants during long-term culturing of infected cells. Furthermore, RD4-2217 at low concentrations (10 or 100 nM), in combination with zidovudine, also completely inhibited viral breakthrough. In addition, RD4-2217 had lower lipophilicity and improved protein binding as compared to its congener RD4-2024 and loviride. These results suggest that RD4-2217, one of the TDA derivatives, is worth pursuing as a candidate drug for the treatment of HIV-1 infections.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013830 Thiadiazoles Heterocyclic compounds composed of a five-membered heterocyclic ring which contains one sulfur and two nitrogen atoms. Thiadiazole
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.
March 1993, Proceedings of the National Academy of Sciences of the United States of America,
M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
May 1995, Journal of medicinal chemistry,
M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives.
June 1997, Antimicrobial agents and chemotherapy,
M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1.
August 1994, Antiviral research,
M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.
June 1991, Molecular pharmacology,
M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from Salvia miltiorrhiza.
July 2002, Antiviral research,
M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
April 1992, Antimicrobial agents and chemotherapy,
M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase.
August 1998, Molecular pharmacology,
M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
January 2017, Journal of virology,
M Fujiwara, and K Ijichi, and Y Hanasaki, and T Ide, and K Katsuura, and H Takayama, and N Aimi, and S Shigeta, and K Konno, and T Yokota, and M Baba
HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
May 1993, Medicinal research reviews,
Copied contents to your clipboard!